Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2017-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-016-1935-1PMID 27915371PMCID PMC11028551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

  2014cited by this paper
• Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination

  2013cited by this paper
• Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression.

  2013cited by this paper
• Anti‐Gr‐1 antibody depletion fails to eliminate hepatic myeloid‐derived suppressor cells in tumor‐bearing mice

  2012cited by this paper
• Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

  2012cited by this paper
• Histone deacetylase inhibition facilitates GM‐CSF‐mediated expansion of myeloid‐derived suppressor cells in vitro and in vivo

  2011cited by this paper
• Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

  2011cited by this paper
• Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

  2010cited by this paper
• Myeloid-derived suppressor cell heterogeneity and subset definition.

  2010cited by this paper
• 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

  2010cited by this paper
• Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels.

  2010cited by this paper
• A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

  2010cited by this paper
• Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

  2009cited by this paper
• Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells

  2008cited by this paper
• Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

  2008cited by this paper
• Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1

  2008cited by this paper
• Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma

  2007cited by this paper
• The terminology issue for myeloid-derived suppressor cells.

  2007cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

  2006cited by this paper
• Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

  2006cited by this paper
• Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

  2005cited by this paper
• Prospects: Histone deacetylase inhibitors

  2005cited by this paper
• Derangement of immune responses by myeloid suppressor cells

  2004cited by this paper
• All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

  2003cited by this paper
• The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

  2003cited by this paper
• Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

  2001cited by this paper
• Histone deacetylase inhibitors as new cancer drugs

  2001cited by this paper
• Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.

  2001cited by this paper
• Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1

  2000cited by this paper
• Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.

  2000cited by this paper
• Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats

  1999cited by this paper

• Histone acetylation modulators in breast cancer

  2025cites this paper
• The epigenetic hallmarks of immune cells in cancer

  2025cites this paper
• Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects

  2025cites this paper
• Epigenetic Regulation of Immune Responses in Endocrine-Related Cancers and Its Role in Immunotherapy

  2025cites this paper
• Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations

  2025cites this paper
• Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

  2024cites this paper
• Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells

  2024cites this paper
• Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications

  2024cites this paper
• Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.

  2024cites this paper
• Computer-aided Drug Discovery of Epigenetic Modulators in Dual-target Therapy of Multifactorial Diseases.

  2024cites this paper
• 5-Fluorouracil Effectively Depletes Tumor Induced Myeloid Derived Suppressor Cells in 4T1 Mammary Carcinoma Model

  2024cites this paper
• Unleashing precision: a review of targeted approaches in pleural mesothelioma.

  2024cites this paper
• The Epigenetic Modifiers HDAC2 and HDAC7 Inversely Associate with Cancer Stemness and Immunity in Solid Tumors

  2024cites this paper
• The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.

  2023cites this paper
• Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer

  2023cites this paper
• Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses

  2023cites this paper
• Function of reactive oxygen species in myeloid-derived suppressor cells

  2023cites this paper
• Tumor microenvironment, histone modifications, and myeloid-derived suppressor cells.

  2023cites this paper
• Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells.

  2023cites this paper
• Epigenetic regulation and therapeutic targets in the tumor microenvironment

  2023cites this paper
• Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy

  2023cites this paper
• Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity

  2023cites this paper
• Epigenetic Perspective of Immunotherapy for Cancers

  2023cites this paper
• Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment.

  2022cites this paper
• Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy

  2022influential citation
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• Epigenetic engineering for optimal chimeric antigen receptor T cell therapy

  2022cites this paper
• Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

  2022cites this paper
• Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

  2022cites this paper
• Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies

  2022cites this paper
• Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies

  2022cites this paper
• Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy

  2022cites this paper
• Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model

  2022cites this paper
• Tumor-related stress regulates functional plasticity of MDSCs.

  2021cites this paper
• The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells

  2021cites this paper
• Epigenetic modulation of antitumor immunity for improved cancer immunotherapy

  2021cites this paper
• Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy

  2021cites this paper
• Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition

  2021cites this paper
• Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma

  2021cites this paper
• Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells

  2021cites this paper
• URRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION

  2021cites this paper
• Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

  2021cites this paper
• Pharmacogenomics for Immunotherapy and Immune-related Cardiotoxicity.

  2020cites this paper
• Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

  2020cites this paper
• Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.

  2020cites this paper
• Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

  2020cites this paper
• A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

  2019cites this paper
• Overcoming immune suppression with epigenetic modification in ovarian cancer.

  2019cites this paper
• Immunological Effects of Epigenetic Modifiers

  2019cites this paper
• Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?

  2019cites this paper
• The emerging role of neutrophils in neurodegeneration.

  2019cites this paper
• Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.

  2019cites this paper
• The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy

  2019cites this paper
• Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy

  2019cites this paper
• Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model.

  2019cites this paper
• Immune Checkpoint Molecules and Cancer Immunotherapy

  2019cites this paper
• Effect of Pharmaceutical Compounds on Myeloid-Derived Suppressor Cells

  2018cites this paper
• The use of alpha-fetoprotein for the treatment of autoimmune diseases and cancer.

  2018cites this paper
• mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells

  2018cites this paper
• Tumor immunotherapy—the potential of epigenetic drugs to overcome resistance

  2018cites this paper
• Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function

  2018cites this paper
• The interplay between neutrophils and microbiota in cancer

  2018cites this paper
• Does CSF1R Blockade Turn into Friendly Fire?

  2017cites this paper
• Immunological effects of everolimus in patients with metastatic renal cell cancer

  2017cites this paper
• Small-Molecule Targets in Immuno-Oncology.

  2017cites this paper
• Cancer Is the Innate Immunity Fault

  2017cites this paper